Literature DB >> 23071066

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

Qiong J Wang1, Ken-Ichi Hanada, Paul F Robbins, Yong F Li, James C Yang.   

Abstract

Clear cell renal cell carcinoma (RCC) is considered an immunogenic tumor, but it has been difficult to identify tumor-infiltrating lymphocytes (TIL) that show in vitro tumor recognition. We compared the characteristics of fresh RCC TIL to peripheral blood lymphocytes (PBL) or melanoma TIL. Our results showed that RCC TIL contained fewer CD27(+) T cells, and fewer naïve and central memory (CM) T cells, but more effector memory (EM) T cells than melanoma TIL or renal PBL. We hypothesized that factors in the RCC microenvironment were skewing TIL phenotype toward EM. One possibility was the expression of CD70 on nearly all human RCCs, but not melanomas. Differentiation of naïve T cells to EM cells only occurred from CD70 costimulation in concert with T-cell receptor (TCR) stimulation (signal one), suggesting that EM TIL responding to CD70 would be enriched for T cells reactive with local antigens, including those associated with RCC. Clonotypic analysis of TCRs in fresh RCCs showed that EM T cells were more clonally expanded than CM or naïve T cells, and the clonal expansion occurred at the tumor site as oligoclonal TCRs were distinct from PBL TCRs from the same patient. In addition, we found that 2 TCRs from the highly represented EM TIL clones, when reexpressed in fresh PBL, recognized an MHC-class II or MHC-class I-restricted antigens shared by multiple RCC lines. Our results suggest that RCC-reactive TIL do exist in situ, but may be difficult to recover and study because of proliferative exhaustion, driven by tumor-expressed CD70.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23071066      PMCID: PMC3513562          DOI: 10.1158/0008-5472.CAN-12-0588

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  CD27 is required for generation and long-term maintenance of T cell immunity.

Authors:  J Hendriks; L A Gravestein; K Tesselaar; R A van Lier; T N Schumacher; J Borst
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

2.  Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions.

Authors:  Kiki Tesselaar; Ramon Arens; Gijs M W van Schijndel; Paul A Baars; Martin A van der Valk; Jannie Borst; Marinus H J van Oers; René A W van Lier
Journal:  Nat Immunol       Date:  2002-12-09       Impact factor: 25.606

3.  Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma.

Authors:  Jörg Wischhusen; Gundram Jung; Ivan Radovanovic; Christoph Beier; Joachim P Steinbach; Andreas Rimner; Huatao Huang; Jörg B Schulz; Hiroko Ohgaki; Adriano Aguzzi; Hans-Georg Rammensee; Michael Weller
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

4.  Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice.

Authors:  Pablo Penaloza-MacMaster; Ata Ur Rasheed; Smita S Iyer; Hideo Yagita; Bruce R Blazar; Rafi Ahmed
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

5.  Expression of interleukin-10 is inversely correlated with distant metastasis of renal cell carcinoma.

Authors:  Noriyasu Uwatoko; Tetsuji Tokunaga; Hiroyuki Hatanaka; Hideo Osada; Tsutomu Kawakami; Hitoshi Yamazaki; Yoshiyuki Abe; Hiroshi Kijima; Yoshito Ueyama; Masato Nakamura
Journal:  Int J Oncol       Date:  2002-04       Impact factor: 5.650

6.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

7.  Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.

Authors:  D J Schendel; B Gansbacher; R Oberneder; M Kriegmair; A Hofstetter; G Riethmüller; O G Segurado
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

8.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779

9.  CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool.

Authors:  Jenny Hendriks; Yanling Xiao; Jannie Borst
Journal:  J Exp Med       Date:  2003-10-27       Impact factor: 14.307

10.  Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation.

Authors:  Ramon Arens; Koen Schepers; Martijn A Nolte; Michiel F van Oosterwijk; René A W van Lier; Ton N M Schumacher; Marinus H J van Oers
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more
  33 in total

1.  Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer.

Authors:  Yunmei Liao; Juanjuan Ou; Jia Deng; Peiliang Geng; Rui Zeng; Yi Tian; Houjie Liang; Bing Ni; Zhihua Ruan
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

2.  Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma.

Authors:  Peter J Siska; Kathryn E Beckermann; Frank M Mason; Gabriela Andrejeva; Allison R Greenplate; Adam B Sendor; Yun-Chen J Chiang; Armando L Corona; Lelisa F Gemta; Benjamin G Vincent; Richard C Wang; Bumki Kim; Jiyong Hong; Chiu-Lan Chen; Timothy N Bullock; Jonathan M Irish; W Kimryn Rathmell; Jeffrey C Rathmell
Journal:  JCI Insight       Date:  2017-06-15

Review 3.  Use of dual-energy CT for renal mass assessment.

Authors:  Shanigarn Thiravit; Christina Brunnquell; Larry M Cai; Mena Flemon; Achille Mileto
Journal:  Eur Radiol       Date:  2020-11-18       Impact factor: 5.315

4.  Rho GDP dissociation inhibitor-β in renal cell carcinoma.

Authors:  Christoph-Alexander von Klot; Natalia Dubrowinskaja; Inga Peters; Jörg Hennenlotter; Axel S Merseburger; Arnulf Stenzl; Markus A Kuczyk; Jürgen Serth
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

5.  Immune signature of tumor infiltrating immune cells in renal cancer.

Authors:  Katharina Geissler; Paolo Fornara; Christine Lautenschläger; Hans-Jürgen Holzhausen; Barbara Seliger; Dagmar Riemann
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

6.  Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Authors:  Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

Review 7.  Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Authors:  M H Geukes Foppen; M Donia; I M Svane; J B A G Haanen
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

Review 8.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

9.  Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.

Authors:  Leiping Fu; Gang Wang; Maria M Shevchuk; David M Nanus; Lorraine J Gudas
Journal:  Cancer Res       Date:  2013-02-27       Impact factor: 12.701

Review 10.  Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Authors:  James H Finke; Pat A Rayman; Jennifer S Ko; Judy M Bradley; Sandra J Gendler; Peter A Cohen
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.